HIND: Vyome Therapeutics Price to Sales

Corporate company logo of ReShape Lifesciences (HIND)

Vyome Holdings Inc delegates clinical testing and product manufacturing to external contractors, creating a heavy reliance on vendors. The P/S multiple trend on GURU.Markets visualizes this process, with the current metric standing at 72.70. The company is also implementing minimally invasive obesity treatments in collaboration with clinics, while simultaneously modernizing its facilities to scale immunotherapy production in the future.

ReShape Lifesciences - HIND Market Cap to Revenue (period 08/16/2025 - 11/18/2026)

Metric breakdowns and analytics for reshapelifesciences.com (HIND)

- stock price and consensus target price:
General company analysis:HIND - ReShape Lifesciences
Mass-produced product of Vyome Holdings Inc

The P/S ratio determines the market value of a unit of revenue, allowing for the identification of fair business valuation boundaries through the analysis of price corridors and export potential. By analyzing the divergence of the P/S from its historical average, an investor assesses whether the asset is overbought, taking into account the impact of Vyome Holdings Inc. (HIND) strict ESG standards regarding chemical waste disposal on the company's long-term capitalization.

Who Vyome Holdings Inc competes with

argenx - Market Cap to Revenue Ratio|P/S Multiple BNTX (biontech.de)|Abivax Corp (ABVX) - Price to Sales|ADMA Corp - P/S Multiple|Price-to-Sales Ratio PTGX|Immunovant Inc (IMVT) - Price-to-Revenue Ratio|KNSA - Price-to-Revenue Coefficient|GRFS (Grifols Biemat) - P/S Multiple|P/S Multiple Adaptive Biotechnologies Inc.|Price-to-Revenue Ratio Celldex Therapeutics (CLDX)|Price-to-Revenue Coefficient auriniapharma.com|Price-to-Revenue Ratio BioCryst Pharmaceuticals BCRX|Market Capitalization-to-Revenue Ratio VERA|Dianthus Pharma - P/S Multiple|PHVS - P/S Multiple|ABCL: P/S Multiple|TRML (Tourmaline Bio, Inc.) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Intrexon|PHAR - Price-to-Revenue Multiple|P/S Multiple NKTR|Price-to-Revenue Ratio UPB (Upstream Bio Corp)|Price-to-Revenue Ratio Zenas Biopharma, Inc. ZBIO|Price-to-Revenue Coefficient immunome.com (IMNM)|Gossamer Bio Inc - P/S Multiple|Market Capitalization-to-Revenue Ratio KALV (KalVista Pharmaceuticals, Inc.)|SEPN: P/S Multiple|Market Cap to Revenue Pieris Pharmaceuticals Inc|Market Cap to Revenue SVRA|Market Cap to Revenue Rigel Pharmaceuticals (RIGL)|P/S Multiple ANAB|ATXS - Price to Sales|Price-to-Revenue Ratio enGene Corp ENGN|Price-to-Revenue Coefficient RAPT Therapeutics, Inc. (RAPT)|Aerovate - P/S Multiple|ACRS - P/S Multiple|KYTX (Kyverna Therapeutics) - Market Cap to Revenue|Price to Sales Tiziana Life Sciences Ltd. (TLSA)|Market Cap to Revenue CABA|Ventyx Biosciences (VTYX) - Price-to-Revenue Coefficient|P/S Multiple THTX|AVTX (Avalo Therapeutics, Inc) - Market Capitalization-to-Revenue Ratio|P/S Multiple ELDN (eledon.com)|AGEN - Market Cap to Revenue|CLYM - Price-to-Revenue Ratio|Price-to-Sales Ratio ZURA|ATYR: P/S Multiple|Adagene Corp (ADAG) - P/S Multiple|Market Cap to Revenue IMA|Shattuck Labs, Inc. - Price-to-Sales Ratio|Price-to-Revenue Ratio Equillium Inc (EQ)|P/S Multiple Connect Biopharma Holdings (CNTB)|Price-to-Revenue Ratio Immunic, Inc. IMUX|P/S Multiple Atara Biotherapeutics ATRA|IFRX - Price-to-Revenue Ratio|XFOR: Price-to-Revenue Ratio|ACET: P/S Multiple|CELU - Price-to-Revenue Coefficient|Price-to-Revenue Ratio inmunebio.com|Market Cap to Revenue Ratio BRNS (barinthusbio.com)|P/S Multiple KZR|P/S Multiple SAB Biotherapeutics, Inc (SABS)|P/S Multiple AKTX (Akari Therapeutics, Plc)|P/S Multiple enlivex.com ENLV|QTTB: Market Cap to Revenue|GOVX - P/S Multiple|Edesa Biotech Inc (EDSA) - Price-to-Revenue Ratio|IBIO - Price-to-Revenue Coefficient|Price-to-Revenue Ratio carismatx.com|XTLB: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Bolt Biotherapeutics Inc. (BOLT)|HCW Biologics - Market Cap to Revenue Ratio|Price-to-Revenue Ratio aptevotherapeutics.com APVO|AIM - Market Cap to Revenue|Aditxt - P/S Multiple|Price-to-Revenue Coefficient GRI Bio Corporation GRI|xortx.com (XRTX) - Price-to-Revenue Ratio|revbiosciences.com (REVB) - P/S Multiple|INDP (Indaptus Corp) - P/S Multiple|Market Cap to Revenue Scinai Immunotherapeutics Ltd (SCNI)|Price-to-Revenue Ratio CalciMedica Inc (CALI)|AFMD (Affimed NV) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALLK (Allakos Inc.)|P/S Multiple HOOKIPA HOOK|IGMS: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ITOS (iTeos)|OCEA: P/S Multiple|TCBP (TC BioPharm Ltd) - Price-to-Revenue Ratio|THRD (Third Harmonic Bio Inc) - P/S Multiple